Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Sep 25, 2023

BUY
$33.3 - $44.82 $427,272 - $575,085
12,831 New
12,831 $478,000
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $427,272 - $575,085
12,831 New
12,831 $478,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $929M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Brookfield Asset Management Inc. Portfolio

Follow Brookfield Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brookfield Asset Management Inc. with notifications on news.